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The incidence, epidemiology, and risk factors of bloodstream infection (BSI) and their impact on transplant
outcomes after umbilical cord blood transplantation (UCBT) are not well deﬁned. Between May 1997 and
December 2012, 202 isolates in 189 episodes of BSI were registered in 134 of 241 patients who underwent
single-unit myeloablative UCBT. Cumulative incidence (CI) of developing at least 1 episode of BSI was 21%,
29%, 34%, 42%, and 52% at days þ7, þ14, þ30, þ100, and þ365, respectively. The median time of onset for the
ﬁrst BSI episode was day þ10 (range, day e7 to þ1217). Early BSI before day 7 was associated with increased
nonrelapse mortality (relative risk [RR], 1.5; 95% conﬁdence interval [CI], 1.1 to 2.3; P ¼ .04), whereas BSI
before day 14 was an independent adverse risk factor for neutrophil recovery (RR, .6; 95% CI, .5 to .9; P ¼ .002).
A higher CD8þ cell dose of the graft was the only variable independently associated with reduced risk of BSI
(RR, .1; 95% CI, .02 to .7; P ¼ .02). The gram-negative rod (GNR) to gram-positive bacteria ratio was .9 before
day þ30 and 1.6 thereafter (P ¼ .03). Escherichia coli (31%) and Pseudomonas sp. (28%) were the most
frequently isolated among GNR. The overall crude mortality rate was 12% at day 7 and was higher for GNR
(18%) compared with gram-positive bacteria (7%) (P ¼ .03). These ﬁndings emphasize the importance of
preventing bacterial infections during conditioning and the very early post-UCBT period.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Bloodstream infections (BSIs) are a leading cause of
morbidity and mortality in patients undergoing allogeneic
hematopoietic stem cell transplantation (allo-HSCT) [1,2]. In
the umbilical cord blood transplantation (UCBT) setting,
characterized by a delayed neutrophil recovery and immune
reconstitution, management of infections is particularly
important. Therefore, efforts to deﬁne the epidemiologic
characteristics, outcome, and prognostic factors of BSI after
UCBT are warranted.edgments on page 760.
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ty for Blood and Marrow Transplantation.Epidemiology and microbial resistance as well as the
clinical characteristics of BSIs and their impact on outcome
may vary with different transplant procedures and stem cell
sources [3,4]. A better knowledge of these features is
essential to guide early interventionwith empirical antibiotic
treatment. Although UCBT has been increasingly used over
the past 2 decades, information on BSI in this speciﬁc sce-
nario is rather scarce. As far as we know, only 3 studies from
Japan have extensively evaluated this complication and were
all restricted to the early post-transplant period [5-7]. Other
reports on infectious complications after UCBT usually
included a relatively low number of patients with few
documented bacteremias [4,8-10]. In addition, the impact of
BSI on transplant outcomes and the risk factors for devel-
opment of this complication have not been deﬁnitely
identiﬁed. Only 1 large registry-based study was able to
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aim of this study was to analyze the incidence of BSI and the
causative organisms, microbial resistance, clinical charac-
teristics, outcome, and prognostic factors in a large series of
adult patients undergoing single-unit myeloablative UCBT at
a single institution.
METHODS
Patients
Between May 1997 and December 2012, 241 consecutive adult patients
with hematologic malignancies underwent myeloablative UCBT from un-
related donors at our institution. The eligibility criteria, described in detail
elsewhere [11,12], were as follows: high-risk hematologic malignancy; no
suitable related donor; need for an urgent transplantation or lack of HLA-
identical unrelated donor after searching in the international registries for
no more than 3months; and an available cord blood unit fulﬁlling minimum
established criteria for both HLA compatibility between donor and recipient
and cell dose. The institutional review board approved the clinical protocols,
and written informed consent was obtained from all patients according to
the declaration of Helsinki.
Conditioning Regimen and Management of Graft-versus-Host-Disease
Myeloablative conditioning regimens were all based on the combina-
tion of thiotepa, busulfan, cyclophosphamide, or ﬂudarabine and antithy-
mocyte globulin. For graft-versus-host disease (GVHD) prophylaxis, all
patients received cyclosporine combined with either prednisone or
mycophenolate mofetil. Patients developing acute GVHD received
high-dose methylprednisolone as initial therapy (2 to 20 mg/kg/day), and
antithymocyte globulin was used in refractory cases. Chronic GVHD was
treated with prednisone (1 mg/kg/day). Details on dose and schedules
were reported elsewhere [12-15].
Supportive Care and Management of Infections
Patients were nursed in high-efﬁciency particulate aireﬁltered rooms.
Intravenous access was achieved with a double-lumen tunneled central
venous catheter. Filgrastim was administered subcutaneously 5 mg/kg/day
from day þ7 until neutrophil recovery. All patients received oral ciproﬂox-
acin prophylaxis (500 mg every 12 hours) until neutrophil recovery or
initiation of broad-spectrum antibiotic therapy.
Pneumocystis jiroveci prophylaxis consisted of co-trimoxazole (320/
1600mg trimethoprim/sulfamethoxazole daily) from day10 to day2 and
was then restarted after neutrophil recovery (2 days a week) to be main-
tained a minimum of 1 year or until stopping immunosuppression. Flu-
conazole prophylaxis (100 mg/day p.o.) was administered in some patients
at the beginning of the study period. From November 2003, i.v. itraconazole
(200 mg/day) was used. When oral intake was feasible, all patients received
antifungal prophylaxis for 6 months or during steroid therapy with a mold-
covering agent.
All blood products were irradiated and leukocyte depleted. Cytomega-
lovirus prophylaxis, infection surveillance, and treatment were described in
detail elsewhere [15]. Nonspeciﬁc i.v. immunoglobulin was administered at
a dose of 500 mg/kg weekly until day þ100 and then monthly within the
ﬁrst year of transplantation.
In case of fever (body temperature 38C) or other signs or symptoms
of infection, patients were treated with empirical broad-spectrum i.v. anti-
biotics following an institutional protocol. At the beginning of the
study period, 30 patients were initially treated with empirical i.v. anti-
pseudomonal penicillin (piperacillin/tazobactam, 4/.5 g every 6 hours) in
combination with amikacin (single daily dose of 20 mg/kg, maximum 1.5 g).
From January 2002, empirical therapy was changed to carbapenem plus
glycopeptide in the remaining 211 patients. Liposomal amphotericin B
(3 mg/kg/day) or, more recently, caspofungin (70 mg initial dose, then
50 mg/day) was added if patients remained febrile for 5 days after the start
of initial therapy. In patients with a microbiologically documented infection,
therapy was modiﬁed, if necessary, according to susceptibility testing.
Before the start of antibiotic therapy, samples of at least 2 sets of blood
cultures (at 20-minute intervals) were collected through a 2-lumen catheter
and peripheral vein. Samples were taken daily through the catheter if fever
persisted. In patients receiving high-dose methylprednisolone, surveillance
blood cultures were performed weekly.
Blood culture samples were processed using an automated BACTEC 9240
(Becton Dickinson, Sparks, NV) or BacT/Alert (Organon Teknika, Durham,
NC) system to process. The central venous catheter was systematically
removed in case of malfunction, thrombosis, documented candidemia,
hemodynamic instability, tunnel infection, and for high suspicion of
catheter-related bacteremia due to persistence of positive blood cultures
despite the use of appropriate antibiotic therapy.Deﬁnitions
Neutrophil recovery was deﬁned as an absolute neutrophil count of
.5109/L or greater on 3 consecutive days. Patients who survived more than
28 days after transplantation and who failed to achieve neutrophil recovery
were considered as graft failures. Time to neutrophil recovery was deﬁned
as the time required to reach the ﬁrst day of neutrophil recovery.
BSI occurring after disease relapse were excluded from the analysis.
Single blood culture isolates were sufﬁcient to consider BSI, regardless of the
presence of a clinical site of infection, except for coagulase-negative
staphylococci (CoNS) and Corynebacterium species other than C. jeikeium,
and other common skin contaminants, which required at least 2 positive
blood culture specimens. BSI was considered polymicrobial if 2 pathogens
were isolated in the same blood culture or in separate blood cultures
obtained in a period of 72 hours. Bacteremia occurring more than 14 days
after a previous episode and separated by repeatedly negative blood
cultures was considered to be another episode of BSI. Pathogens with in-
termediate susceptibility or resistance were considered as resistant. Enter-
obacteria producing extended-spectrum b-lactamases (ESBLs) were deﬁned
as strains with acquired enzymes capable of hydrolyzing and causing
resistance to penicillins, cephalosporins, and monobactams (not cepha-
mycins or carbapenems) inhibited by beta-lactamase inhibitors (like clav-
ulanic acid or tazobactam). Susceptibility studies were done following
Clinical Laboratory and Standards Institute procedures and breakpoints.
Multidrug resistance was deﬁned as acquired nonsusceptibility to at least 1
usually active agent in 3 or more antimicrobial categories following criteria
proposed byMagiorakos et al. [16]. For the purpose of the study, the periods
after transplantation were classiﬁed as early (from days 0 to þ30), inter-
mediate (from days þ31 to þ100), late (from days þ101 to þ365), or very
late (after day þ365).
Data Collection
Data of patients, transplant procedures, and infectious complications
were prospectively collected in all patients undergoing UCBT and then
settled in a computerized database. Clinical charts were additionally
reviewed for inconsistent or missing data. Data collection for the analysis
was stopped on January 1, 2013.
Statistical Analysis
The chi-square test with Yates’ correction and Fisher’s exact test were
used for comparisons of categorical variables. Two-tailed P values were
used. The probabilities of neutrophil recovery, nonrelapse mortality (NRM),
and BSI were estimated by the cumulative incidence method (marginal
probability) [17]. For cumulative incidence analyses of neutrophil recovery,
death in complete remissionwas considered as a competing cause of failure,
relapse was the competing event for NRM, and death and relapse were
competing events for BSI. The Fine and Gray method for competing events
[18] was used for multivariable analysis.
Variables considered for risk factor analysis were age; gender; recipient
weight; recipient cytomegalovirus serology; disease status at trans-
plantation; HLA compatibility; conditioning regimen; GVHD prophylaxis;
type of empirical antibiotic therapy; total nucleated cell count; CD34þ,
CD3þ, CD4þ, CD8þ, CD16þ, CD56þ, and CD19þ cells of the graft; and BSI at
days 7, 14, and 30. BSIs at these time points were considered as a time-
dependent covariate. Correlation between variables was analyzed by
Spearman’s correlation test. Statistical analysis were conducted using R
version 3.0.1 (The CRAN project) [19].
RESULTS
Patient Characteristics
Table 1 shows the main characteristics of the 241 adult
patients who underwent myeloblative UCBT from unrelated
donor. Median age was 34 years (range, 15 to 57), and 148
patients were males. The diagnosis were acute myeloid leu-
kemia/myelodysplastic syndrome (40%), acute lymphoblastic
leukemia (37%), chronic myeloid leukemia (12%), and a
miscellaneous group of other underlying conditions (11%).
One hundred thirteen cord blood recipients (48%) were
transplanted in the early phase, whereas the remaining pa-
tients had amore advanced disease status. Median follow-up
of surviving patients was 73 months (range, 10 to 180).
Cord Blood Unit and Transplant Characteristics
Table 1 shows the characteristics of cord blood units and
those related to the transplant procedure. Except for 11
Table 1
Patient-, Graft- and Transplantation-Related Characteristics
Characteristic Value
No. of patients 241
Age, yr
Median 34
Range 15-57
Gender
Male 148 (61)
Female 93 (39)
Diagnosis
Acute myeloid leukemia/myelodysplastic syndrome 98 (40)
Acute lymphoblastic leukemia 90 (37)
Chronic myeloid leukemia 28 (12)
Chronic lymphoproliferative disorders 19 (8)
Other 6 (3)
Disease status at transplant
Early 113 (48)
Intermediate 62 (25)
Advanced 66 (27)
Cytomegalovirus serologic status before transplantation
Positive 189 (78)
Negative 52 (22)
HLA compatibility
6 of 6 11 (5)
5 of 6 56 (23)
4 of 6 170 (70)
3 of 6 4 (2)
Conditioning regimen
TT þ BU þ CY þ ATG 72 (29)
TT þ BU þ FLU þ ATG 170 (71)
GVHD prophylaxis
Cyclosporine A þ prednisone 164 (68)
Cyclosporine A þ MMF 77 (32)
No. of nucleated cells infused, 107/kg
Median 2.3
Range 1.0-5.8
No. of CD34þ cells infused, 105/kg
Median 1.3
Range .08-21.1
No. of CD8þ cells infused, 106/kg
Median 1.6
Range .5-6.8
Values are number of cases with percents in parentheses (percentages may
not sum to 100 because of rounding), unless otherwise indicated. TT, thio-
tepa; BU, busulfan; CY, cyclophosphamide; ATG, antithymocyte globulin;
FLU, ﬂudarabine; MMF, mycophenolate mofetil.
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remaining 230 patients (95%) received an HLA-mismatched
unit. Donorerecipient disparity in 1 and 2 of 6 antigens
occurred in 56 patients (23%) and 170 patients (70%),
respectively. Four additional patients (2%) received a 3-
antigen mismatched unit. The median number of total
nucleated cells and CD34þ cells infused was 2.3  107/kg
(range, 1.0 to 5.8) and 1.3  105/kg (range, .08 to 21.1),
respectively.
Incidence and Timing of BSI
BSIs were documented in 189 episodes in 134 patients
who underwent CBT. Ninety-two patients had 1 BSI episode
(38%), 30 patients had 2 episodes (12%), 11 had 3 episodes
(5%), and 1 patient had 4 episodes (1%). Cumulative incidence
risk of developing at least 1 episode of BSI was 21% at dayþ7,
29% at day þ14, 34% at day þ30, 42% at day þ100, 52% at
day þ365, and 54% at 4 years.
The median time of onset for the ﬁrst BSI episode was
day þ10 (range, day e7 to þ1217). Seventy-three BSIs (39%)
were documented in 65 patients (27%) before neutrophil
recovery. The distribution of BSI episodes by periods after
transplantation was the following: 98 (52%) during the early
period (median day, þ6), including 3 that occurred duringconditioning; 38 (20%) during the intermediate period
(median day, þ57); 41 (22%) during the late period (median
day, þ139); and 12 (6%) during the very late period (median
day, þ556).
Impact of BSIs on Transplant Outcomes
Neutrophil recovery
Twelve patients died before day þ28 at a median time of
16 days (range, 9 to 24) without evidence of engraftment.
Nine patients assessable for engraftment did not achieve
neutrophil recovery and were considered as primary graft
failures. Two hundred twenty patients experienced neutro-
phil recovery at amedian time of 21 days (range, 9 to 57). The
cumulative incidence of neutrophil recovery at 57 days was
92%. Early BSI before day 14 after UCBT showed a negative
impact in univariable analysis (81% versus 96%; P ¼ .003). In
multivariable analysis, CD34þ cell count (relative risk [RR],
1.1; 95% conﬁdence interval [CI], 1.1 to 1.2; P < .001) and BSI
before day 14 (RR, .6; 95% CI, .5 to .9; P ¼ .002) remained as
independent risk factors for neutrophil recovery.
NRM and causes of death
One hundred thirteen transplant-related deaths occurred
at amedian time of 114 days after transplantation (range, 7 to
3930). The primary causes of death were infection in 66
patients, GVHD in 19 patients, and a variety of transplant-
related causes in the remaining 28 patients. Of the 66
deaths attributable to infection, 28 were bacterial infections,
14 invasive fungal infections, 15 viral infections, 3 mixed
infections, 1 leishmaniasis, and 5 were not microbiologically
documented. The cumulative incidence of NRM at day 100
and at 2 years was 20% and 45%, respectively. Early BSI before
day 7 after UCBT showed a negative impact on 100-day NRM
in univariable analysis (32% versus 16%; P ¼ .04). NRM at day
100 was 21% and 25% (P¼ .8) for early gram-positive bacteria
(GPB) and gram-negative rod (GNR) BSI before day 7,
respectively. In multivariable analysis, diagnosis of acute
leukemia (RR, .5; 95% CI, .3 to .7; P < .001) and BSI before day
7 (RR,1.5; 95% CI, 1.1 to 2.3; P¼ .04) remained as independent
risk factors for NRM.
Risk Factors for BSI
In univariable analysis, CD34þ cell dose infused with a
best cut-off at 1105/kg (P¼ .03) and CD8þ cell dose infused
with a best cut-off at 1.6  106/kg (P < .001) inﬂuenced the
risk of developing BSI. Multivariable analysis showed that a
higher CD8þ cell dose was the only variable independently
associated with reduced risk of BSI (RR, .1; 95% CI, .02 to .7;
P¼ .02). The R correlation coefﬁcient between infused CD34þ
and CD8þ cells was .41 (P < .01).
Etiology of BSIs
Overall, there were 202 isolates over 189 episodes of BSI.
Seventy-six single BSI were due to GPB (40%), 87 to GNRs
(46%), and 13 to fungi (7%). Among 13 polymicrobial BSIs
(7%), 7 were due to GPB and GNRs, 3 to GNRs, 1 to GPB, 1 to
GPB and Candida, and 1 to GNRs and Candida. Detailed eti-
ology by post-transplant period is outlined in Table 2. The
GNR/GPB ratio was .9 in the early period and 1.6 thereafter
(P ¼ .03) and did not change signiﬁcantly during the obser-
vation period.
Gram-positive bacteria
Overall, 85 GPB were isolated (Table 2). The predomi-
nance of GPB before engraftment was mainly with CoNS,
Table 2
Bloodstream Isolates by Transplant Period
Organism Early Intermediate Late Very
Late
All
Periods
Total 102 43 45 12 202
Gram-positive 48 (47) 18 (41) 15 (33) 4 (33) 85 (42)
Staphylococcus
coagulase-negative
29 12 11 4 56
Staphylococcus aureus 4 0 1 0 5
Enterococcus 4 5 2 0 11
Streptococcus viridans 7 0 0 0 7
Corynebacterium
jeikeium
2 1 0 0 3
Streptococcus
agalactiae
1 0 0 0 1
Streptococcus
pneumoniae
1 0 0 0 1
Rhodococcus equi 0 0 1 0 1
Gram-negative 43 (42) 24 (55) 28 (62) 7 (58) 102 (51)
Escherichia coli 20 4 6 2 32
Klebsiella-Enterobacter-
Serratia
2 2 5 0 9
Pseudomonas spp. 8 9 9 3 29
Stenotrophomonas
maltophilia
5 5 1 0 11
Acinetobacter spp. 6 2 2 0 10
Salmonella spp. 0 1 1 2 4
Aeromonas hydrophila 1 0 0 0 1
Proteus mirabilis 0 0 1 0 1
Nontypiﬁed gram
nonfermenter
1 0 2 0 3
Morganella morganii 0 0 0 1 1
Campylobacter spp. 0 1 0 0 1
Fungi 11 (11) 1 (2) 2 (4) 1 (8) 15 (7)
Candida albicans 1 0 0 0 1
Candida glabrata 1 0 0 1 2
Candida krusei 5 0 1 0 6
Candia parapsilosis 2 1 0 0 3
Candida tropicalis 1 0 1 0 2
Blastoschizomyces
capitatus
1 0 0 0 0
Values in parentheses are percents.
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Enterococcus sp. (13%), Streptococcus viridans (8%), and
Staphylococcus aureus (6%). Eleven of 12 (92%) BSIs by
S. aureus or Streptococcus viridans occurred in the neu-
tropenic phase, whereas 7 of 11 (64%) enterococcal infections
appeared after neutrophil recovery. Of these, 7 were due to
Enterococcus faecalis and 4 to Enterococcus faecium. Only 1
isolate of S. aureuswas methicillin-resistant. The distributionFigure 1. Etiology of BSIs caused by GNRs according to the post-transplant
period.of GPB changed signiﬁcantly during the observation period.
CoNS, Streptococcus viridans, and Enterococcus species
accounted for 80%, 2%, and 4% before 2007 and 50%, 15%, and
23% from 2007 onward, respectively (P ¼ .01).
Gram-negative bacteria
Among 102 GNRs (Table 2), Escherichia coli and Pseudo-
monas spp. were the most frequently isolated (31% and 28%
of GNRs, respectively). Stenotrophomonas maltophilia and
Acinetobacter spp. accounted for 11% and 10% of GNRs,
respectively. Isolates had a different distribution according to
the post-transplant period (P ¼ .01) (Figure 1). E. coli repre-
sented 47% of early GNR infections and decreased thereafter,
whereas Pseudomonas spp. and Klebsiella-Enterobacter-Ser-
ratia (KES) were more frequently observed after engraft-
ment. Three Salmonella spp. BSIs were diagnosed in the late
or very late period. No signiﬁcant changes occurred during
the observation period.
Antibiotic susceptibility of the different isolates is shown
in Table 3. Brieﬂy, 67% of E. coli were resistant to ﬂuo-
roquinolones and 77% were ESBL producers. The proportion
of Pseudomonas spp. with multidrug resistance and carba-
penem resistance was 21%. Antibiotic susceptibility did not
change over the observation period but was different ac-
cording to the post-transplant period. Fluoroquinolone
resistance was 70% in the early period and 25% afterward
(P< .001). Multidrug resistancewas present in 83% of isolates
in the early period and 33% afterward (P< .001). Carbapenem
resistance was 30% before day þ100 and 9% afterward
(P < .03).
Fungemia
Fourteen of 15 fungal BSIs (13 single, 2 polymicrobial)
were due to Candida spp. C. kruseiwas isolated in 6 episodes,
C. parapsilosis in 3 episodes, and C. tropicalis and C. glabrata in
2 occasions each. C. albicans was only isolated in 1 case.
Eleven fungal BSIs occurred during neutropenia.
Outcome of BSIs
Mortality according to the causative microorganism and
transplant period is detailed in Table 4. The overall crude
mortality rate was 12% at day 7 and 23% at day 30. Regarding
BSI etiology, the 7-day mortality rate was higher for GNRs
(18%) compared with GPB (7%), fungi (8%), and polymicrobial
(8%) infections (P¼ .03). Mortality rates were not statistically
different for CoNS and other GPB at day 7 (9% and 0%,
respectively; P¼ .3) and at day 30 (19% and 25%, respectively;
P ¼ .8). Within GNRs, 7-day and 30-day mortality rates were
highest for Acinetobacter spp. (50% and 88%), followed by
S. maltophilia (25% and 38%), KES (25% and 25%), Pseudo-
monas spp. (17% and 25%), and E. coli (7% and 10%) (P ¼ .03
and P ¼ .002 for 7-day and 30 day mortality rates, respec-
tively). Differences in mortality were also observed accord-
ing to carbapenem susceptibility. Mortality rates at day 7 and
day 30 for BSI caused by GNRs resistant or susceptible to
carbapenem were 39% and 12% (P ¼ .02) and 61% and 18%
(P < .001), respectively. Mortality rate did not change
signiﬁcantly in the different post-transplant phases or
throughout the observation period.
DISCUSSION
This study shows that BSI, the most common severe
complication after myeloablative UCBT, was more frequently
observed in patients receiving cord blood units with lower
CD34þ and CD8þ cell doses. In addition, early BSI was also
Table 3
Antibiotic Resistance in Gram-Negative Isolates
Organism Resistant to
Fluoroquinolone
Resistant to Third-
Generation
Cephalosporin*
Resistant to
Piperacillin-
Tazobactam
Resistant to
Carbapenem
Resistant to
Aminoglycoside
ESBL
Producers
MDR
Bacteria
E. coli 21 (67) 7 (23) 3 (10) 0 (0) 0 (0) 24 (77) 23 (74)
Pseudomonas spp. 6 (21) 5 (17) 4 (14) 6 (21) 3 (11) d 6 (21)
Klebsiella spp. 0 (0) 1 (25) 2 (50) 0 (0) 1 (25) 2 (50) 2 (50)
Enterobacter-Serratia spp.y 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
S. maltophilia 4 (36) 1 (9) d d d d 11 (100)
Acinetobacter spp. 10 (100) 10 (100) 10 (100) 7 (70) 4 (40) d 10 (100)
Salmonella spp. 0 (0) 0 (0) 0 (0) 0 (0) d 0 (0) 0 (0)
MDR indicates multidrug resistant.
Values are number of cases with percents in parentheses.
* In Pseudomonas spp. or S. maltophilia susceptibility to ceftazidime.
y In Serratia spp. tobramycin was not evaluated.
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100-day NRM. We observed predominance of GNRs that
were associated with a higher mortality rate.
This retrospective, single-center study included a large
series of adults with a variety of hematologic malignancies,
althoughmost had acute leukemia, that received UCBTover a
long period of time (almost 15 years). Patients received a
relatively homogeneous conditioning regimen and support-
ive care, including infectious prophylaxis, empirical treat-
ment of febrile neutropenia, and procedures for blood sample
extraction and processing. Unlike all previous studies that
focused on BSI after UCBT [5-7], all patients were followed
throughout the observation period and information
regarding BSIswas collected beyond the early post-transplant
period. This allowed us to analyze differences in epidemi-
ology at different time points. Because microbiologic epide-
miology may vary signiﬁcantly over time and in different
institutions, some of the data should be interpreted with
caution and may only be applicable in this speciﬁc setting.
We conﬁrmed previous ﬁnding suggesting that early BSI
was an independent risk factor for NRM in adults undergoing
UCBT [7]. Interestingly, we also found early BSI to be a strong
and independent predictor of neutrophil recovery, as a time-
dependent covariate. These ﬁndings highlight the impor-
tance of preventing early bacterial infection. The exact
mechanism by which BSI can interfere with engraftment is
unknown.We could hypothesize that bacterial endotoxins or
host cytokines could have hampered homing and differen-
tiation of cord blood progenitor cells. However, the possi-
bility that early BSI could be a surrogate marker of graft
cellularity cannot be ruled out.
BSIs were frequent complications after UCBT with a cu-
mulative incidence of 42% at day 100 and 54% at 4 years,Table 4
Mortality Rate after BSI Episodes According to the Etiologic Agent
Organism Number of
Episodes
7-Day
Mortality
N (%)
30-Day
Mortality
N (%)
Total 189 23 (12) 44 (23)
Gram-positive 76 5 (7) 16 (21)
Gram-negative 87 16 (18) 24 (28)
Other Gram- 11 2 (18) 2 (18)
E. coli 28 2 (7) 3 (10)
Pseudomonas spp. 24 4 (17) 7 (29)
KES 8 2 (25) 2 (25)
S. maltophilia 8 2 (25) 3 (38)
Acinetobacter spp. 8 4 (50) 7 (88)
Fungi 13 1 (8) 2 (15)
Polymicrobial 13 1 (8) 2 (15)which was in line with previously reported rates using other
stem cell sources [2,20]. Although UCBT is characterized by a
longer time to neutrophil recovery, to date this procedure has
not been consistently associated with an increased risk of
bacterial infections [4,21]. Two studies from the University of
Tokyo reported a cumulative incidence of BSIs of 32% at day
100 for reduced intensity [5] and 12% at day 30 for myeloa-
blative conditioning [6]. An additional study from the Japan
Cord Blood Bank Network [7] reported a cumulative incidence
of 21% at day 100. The difference is likely due to local epide-
miology and transplant, infectious, and laboratory procedures.
However, the incidence of BSI could have been under-
estimated when focusing on early infections. It should be
noted that in our study around 60% of BSI episodes were
observed after neutrophil recovery and around 30% after
dayþ100. Regarding the analysis of risk factors for BSI, to date
no risk factors have been identiﬁed in the UCBT setting except
for an increased incidence in the adult population. We
describe here for the ﬁrst time the impact of cord blood unit
cell dose, in terms of CD34þ cells and CD8þ cells, on the risk of
BSI. This ﬁnding is expected because we previously described
the importance of these markers on neutrophil recovery [11].
Except for a small predominance of GPB before engraft-
ment, which was mainly due to CoNS, GNRs were more
frequently observed in all the remaining post-transplant
periods and overall. This is in contrast to most published
studies demonstrating that gram-positive organisms were
responsible for most BSIs after allo-HSCT [20,22,23],
including UCBT [5-7,9]. Signiﬁcant variations in epidemi-
ology or antibiotic susceptibility over time were not found,
except for an increase of Streptococcus viridans and Entero-
coccus species after 2007. However, ﬁndings on the different
transplant periods merit some attention. The early post-
transplant period was characterized by the presence of
S. aureus, Streptococcus viridans, E. coli, and Candida species
that were replaced by Enterococcus species, Pseudomonas
spp., and KES in the postneutropenic phase. Of note, 3 Sal-
monella spp. were isolated after day 100.
Regarding antibiotic susceptibility, isolateswere frequently
resistant. A high rate ofﬂuoroquinolone resistancewasmainly
observed during the early post-transplant period, corre-
sponding with the widespread use of ciproﬂoxacin prophy-
laxis.Whether or not this policy should be changed because of
the high rate of resistance is a difﬁcult matter, because the
efﬁcacy of this procedure was not evaluated in the present
study and the number of quinolone-sensitive BSIs that were
potentially prevented is not known. This pattern of resistance
is particularly important to guide the choice of empiri-
cal antibiotic treatment. The observation of a high rate of
J. Sanz et al. / Biol Blood Marrow Transplant 21 (2015) 755e760760ESBL-producer enterobacteria, carbapenem-resistant Pseudo-
monas strains, and frequent isolates of S. maltophilia and Aci-
netobacter spp. may reﬂect the high-risk population included
in this study. Most patients had received multiple prior high-
dose chemotherapy cycles, with prolonged neutropenia, and
high exposure to antimicrobial treatment and were in need of
an urgent transplant. Knowledge of this epidemiology is
crucial to design protocols and strategies for antibiotic pro-
phylaxis and empirical antimicrobial treatment of fever in
UCBT recipients.
Evaluation of outcome after BSI and the detection of
prognostic factors affecting mortality are important matters.
Early crude mortality rate was analyzed in an effort to
overcome bias and discriminate from other variables that can
inﬂuence mortality in the allo-HSCT setting. Seven-day and
30-day mortality rates were similar to those previously re-
ported after high-risk transplants [21]. As expected, mortal-
ity was higher for GNRs compared with GPB, and this
difference remained if CoNS were excluded from the analysis
(data not shown). The main contributors to mortality were
the etiology of BSI and resistance to carbapenem, which was
used as empirical therapy of febrile neutropenia.
In conclusion, we highlighted the importance of BSI after
myeloablative UCBT in adults with hematologic malignancies,
particularly with the use of cord blood units with low cellu-
larity. Interestingly, early BSI not only increased NRM but
hampered neutrophil recovery. These ﬁndings emphasize the
importance of prevention of bacterial infections during con-
ditioning and the very early post-UCBT period.
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